At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 546 enrolled
Drug / intervention
XIENCE V EECSS +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval Randomized Control Trial (RCT)
In Brief
A Phase 4 clinical trial evaluating XIENCE V EECSS and CYPHER SELECT PLUS SECSS for Coronary Occlusion and 7 related conditions. Completed, enrolled 546 participants across 2 sites.
Detailed Summary
This is a prospective, randomized, active-controlled, open label, parallel two-arm, multi-center, post-approval study descriptively comparing the XIENCE V EECSS to the CYPHER SELECT PLUS Sirolimus-Eluting Coronary Stent System (SECSS) ("CYPHER SELECT PLUS") during commercial use in China.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Occlusion, Thrombosis (Stent Thrombosis), Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis, Coronary Disease, Coronary Artery Disease, Coronary Restenosis
CountriesChina
Collaborators--
Timeline
Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartAug 2010
First PostedAug 2010
Primary CompletionOct 2012
Study CompletionSep 2014
TodayJul 2026
First PostedAug 10, 2010
Enrollment StartAug 1, 2010
Primary CompletionOct 1, 2012
Study CompletionSep 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 15.9 years ago
Interventions
XIENCE V EECSSdevice
Patients who will receive this stent.
CYPHER SELECT PLUS SECSSdevice
Patients who will receive this stent.